Dr Frimberger is internationally recognised as a leading veterinary oncologist. Dr Frimberger attended the prestigious University of Pennsylvania Veterinary School in the US where she graduated with a high distinction before specialising in veterinary oncology. She trained as a resident at Tufts University and undertook a research fellowship at University of Massachusetts Cancer Centre.

Dr Frimberger is recognised by her peers as an expert in clinical veterinary oncology having led multiple clinical trials, published extensively in peer-reviewed journals and textbooks and is an invited speaker at national and international conferences. Dr Frimberger is a Co-Director of Veterinary Oncology Consultants. In 2013 she was engaged by PharmAust to oversee the company’s veterinary clinical development program.

Dr Schirvel was previously Head of Business Development and Licensing (BD&L) at Elanco, one of the world’s major animal health companies. Prior to this, he served as Global Head BD&L (Therapeutics and Parasiticides) at Novartis Animal Health until it was acquired by Elanco. He was also Global Head of BD&L at Vétoquinol, a top-ten Animal Health Company, and held several senior positions in Global Marketing and Strategic Development at Merial.

Dr Schirvel is a leading global animal health executive with an extensive background in product licensing, corporate strategy, marketing and alliance management. He brings a wealth of contacts at the highest levels in global animal health companies, which will be of great assistance in PharmAust’s business and clinical development activities.